Skip to main content
Premium Trial:

Request an Annual Quote

Immunovia, Proteomedix to Collaborate on R&D Efforts

NEW YORK – Proteomics-based diagnostics firms Immunovia and Proteomedix announced on Monday that they have entered a strategic partnership to advance both companies' research and development efforts.

The companies did not provide details about the partnership but said that it will complement each firm's R&D capabilities and give them a more flexible R&D organization while increasing their R&D productivity. The deal will also allow Immunovia to focus internal resources on the commercialization of its ImmRay PanCan-d test, further accelerating the test's rollout, the Swedish firm said. 

The collaboration will enable " both companies to faster take critical steps forward by leveraging our combined expertise to increase R&D efficiency," Proteomedix CEO Helge Lubenow said in a statement. It will also demonstrate "how our biomarker assay development expertise can be deployed beyond prostate cancer," Lubenow said.

Proteomedix currently offers its blood-based prostate cancer test Proclarix, which relies on proteomics technology to measure cancer-associated proteins, in Europe. It launched the assay in 2020.

The deal "will combine leading proteomics-based researchers with state-of-the art capabilities from both companies to create an outstanding R&D platform," Immunovia CEO and President Philipp Mathieu added. The company noted that Linda Dexlin Mellby, Immunovia's VP of research and development, will leave the company in November as a result of the partnership. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.